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ABSTRACT
Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic 
Factor for Recurrence after Curative Resection followed by Adjuvant 
Chemotherapy in Stage III Colon Cancer
Chang-gon Kim
Department of Medicine
The Graduate School, Yonsei University 
(Directed by Professor Sang Joon Shin)
Colorectal cancer is frequently diagnosed and leading cause of cancer death 
worldwide. Patients with adjuvant chemotherapy gained survival benefit with 
minimizing recurrence. So it is a necessary to establish more accurate prognostic and 
prognostic markers for cancer recurrence and survival to improve treatment for 
individual patients because of considerable diversity and heterogeneity among tissues of 
the same TNM stage. 
Serum carcinoembryonic antigen (CEA) is a 201 kDa highly glycosylated antigen 
and was demonstrated to be a tumor marker for colon cancer over 45 years ago. With 
the disruption of normal tissue architecture in malignancy and loss of polarization of 
neoplastic cells located deep inside the tumor glandular tissue, CEA may expressed on 
the whole cell surface and is eventually shed into the blood stream leading to a rise in 
serum CEA levels. So before resection of colon cancer, most guidelines suggest routine 
measurement of preoperative CEA, mainly for monitoring postoperative surveillance. 
However, there has been some controversy about the significance of the preoperative 
CEA level as a prognostic factor of recurrence. Furthermore, few previous reports have 
considered optimal cutoff values for CEA level.
Here we evaluated the optimal cutoff values for the CEA and whether an elevated 
preoperative CEA levels represents an independent prognostic factor for recurrence 
after curative resection of stage III colon cancer. By this study, we strongly recommend 
routine preoperative CEA measurement in stage III colon cancer patients and inclusion 
of this result in risk stratifications. Also further large scale studies are necessary to 
determine a specific valid cutoff values for preoperative CEA level to achieve more 
accurate prognostic stratifications.
----------------------------------------------------------------------------------------
Key words : stage III colon cancer, carcinoembryonic antigen, prognostic 
factor of recurrence 
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I. INTRODUCTION
Colorectal cancer is one of the most common solid tumours and one of the most 
frequent causes of cancer-related mortality worldwide [1]. Approximately 70% of all 
colorectal cancer is colonic in origin. In the past, colorectal cancer was commonly 
staged using the classic Dukes anatomical staging system based on the involvement of 
the bowel wall and regional lymph nodes. In recent years, however, colon cancer has 
generally been anatomically staged by using the TNM system, based on the anatomic 
extent of the primary tumour (T stage), the nodal status (N stage), and distant spread or 
metastases (M stage) [2]. In stage III colon cancer (node-positive non-metastatic 
tumours), the benefit of adjuvant chemotherapy following curative resection has been 
well established, with definitive trials for FOLFOX (5-fluorouracil [5-FU], leucovorin 
[LV], and oxaliplatin) [3], XELOX (capecitabine/oxaliplatin) [4], and FLOX (5-FU, 
LV, and oxaliplatin) [5] completed within the past 15 years. However, accurate 
determination of an individual patient’s prognosis remains difficult.
Serum carcinoembryonic antigen (CEA) was demonstrated to be a tumour marker for 
colon cancer over 45 years ago [6]. With the disruption of normal tissue architecture in 
malignancy and the loss of polarization of neoplastic cells located deep inside the 
tumour glandular tissue, CEA may be expressed on the entire cell surface and is 
eventually secreted into the bloodstream, leading to a rise in serum CEA levels [7-10]. 
Before the resection of colon cancer is performed, the guidelines of the National 
Comprehensive Cancer Network (NCCN) suggest routine measurement of preoperative 
CEA levels, mainly for the purpose of subsequent postoperative surveillance (NCCN, 
2014). Consistent elevation in serum CEA levels is a concerning sign of disease 
recurrence, and CEA remains the only widely used serum tumour marker that has been 
shown to correlate sufficiently with colon cancer activity, which is why it is used 
reliably during follow-up [11]. In 2000, based on the results of several studies showing 
serum CEA to be a stage-independent poor prognostic factor in colorectal cancer, the 
Colorectal Working Group of the American Joint Committee on Cancer (AJCC) 
proposed the inclusion of the serum level of CEA (C stage) at disease presentation into 
conventional TNM staging of colorectal cancer [12]. However, there has been some 
controversy about the significance of the preoperative CEA level as a preognostic factor 
for recurrence [13-14]. Furthermore, few previous reports have considered optimal 
cut-off values for CEA levels [15-16].
Therefore, the objectives of the present study were to evaluate the optimal cut-off value 
for the CEA level and to determine whether an elevated preoperative CEA level 
represents an independent prognostic factor for recurrence following curative resection 
of stage III colon cancer.
II. MATERIALS AND METHODS
1. Patients and methods
Prospectively accrued data from patients with stage III colon cancer without perforation 
or obstruction who underwent elective curative surgery between April 2009 and 
December 2014 at Severance Hospital were retrieved (N = 278, Fig. 1). These patients 
had originally been enrolled for an epidemiologic study of KRAS mutation in stage III 
colon cancer patients, and we were unable to find any statistically significant impact of 
KRAS mutation on disease-free survival (DFS) or overall survival (OS, Sup. 1). In the 
present study, curative resection was defined as the absence of any gross residual 
tumour from the surgical bed and a surgical resection margin that was pathologically 
negative for tumour invasion. Patients who did not have preoperative CEA levels 
checked (N = 8) and those who received chemotherapy without oxaliplatin (Xeloda 
[capecitabine]; N = 2) were excluded to achieve a more homogeneous study population. 
Data obtained included patient demographics (age, sex), smoking history, tumour 
location, stage (including T and N stage), retrieved lymph node number, tumour 
differentiation, lymphovascular invasion, perineural invasion, adjuvant 
chemotherapeutic regimen, DFS, and OS. An ever smoker was defined as a person who 
had smoked 100 or more cigarettes in his/her lifetime, and a current smoker was defined 
as a person who smoked at the time of preoperative CEA measurement. Patients were 
followed up at 3-month intervals for the first 2 years after the surgery, at 6-month 
intervals for the next 3 years, and annually thereafter. The median follow-up duration 
was 26 months. If a suspicion of recurrence existed, follow-up examinations included a 
clinical evaluation, physical examination, serum CEA assay, chest radiography or 
computed tomography (CT), abdominopelvic CT, colonoscopy, and positron emission 
tomography (PET), if available. Recurrence was determined on clinical and radiological 
examinations or via histological confirmation.
2. Measurement of serum CEA
Serum CEA was measured preoperatively by using the Elecsys 2010 
electrochemiluminescence immunoassay (Roche Diagnostics GmbH, Mannheim, 
Germany) in one laboratory. The normal range for serum CEA is 0–4.9 ng/mL at our 
institution.
3. Staging and pathological analysis
Staging was principally based on the guidelines for colon cancer in the 7th edition of the 
AJCC Cancer Staging Manual. Preoperative workup included pathologic tissue review; 
total colonoscopy; complete blood count; biochemistry profile; and baseline chest, 
abdominal, and pelvic CT. Experienced pathologists from our institution reviewed the 
surgical specimens and confirmed the diagnosis.
4. Statistical analysis
Data were analysed using statistical software package SPSS for Windows software, 
version 23.0 (SPSS Inc., Chicago, IL, USA). Clinical and pathological variables were 
compared across groups by using the independent samples t-test and χ2 tests for 
continuous and categorical variables, respectively. Survival plots were estimated by 
using the Kaplan-Meier method, and differences in survival distributions were evaluated 
by using the log-rank test. In multivariate analysis, a Cox proportional hazards model 
was used to analyse the effect of specified risk factors on DFS. A value of P < 0.05 was 
considered statistically significant.
Figure 1. Patient selection
Index　 Value (ng/mL) Standard error
Mean value 11.58 2.08010
Standard deviation 34.05
Median value 3.23
Minimum value 0.37 　
Maximuml value 393.68 　
Skewness 8.020 .149
Kurtosis 77.398 .297
III. RESULTS
1. Distribution of preoperative serum CEA levels
To determine the distribution of preoperative serum CEA levels, descriptive statistics 
were calculated and a histogram was constructed (Table 1, Fig. 2). The median and 
mean values for the preoperative serum CEA level were 3.23 ng/mL and 11.58 ng/mL, 
respectively.
Table 1. Descriptive statistics for preoperative serum CEA level
Figure 2. Histogram for preoperative serum CEA level
CEA threshold   
(ng/mL) χ2 for DFS
P-value 
for χ2
Hazard ratio for   
recurrence
(95% CI)
P-value for   
Hazard ratio
<6.5, ≥=6.5 2.570342 0.108884 1.587   (0.780-3.227) 0.202525
<6.0, ≥=6.0 3.513848 0.060858 1.733   (0.857-3.501) 0.125695
<5.5, ≥=5.5 8.136123 0.004339 2.438   (1.217-4.886) 0.011965
<5.0, ≥=5.0 6.213049 0.012681 2.208   (1.104-4.416) 0.025130
<4.5, ≥=4.5 5.443267 0.019644 2.083   (1.043-4.163) 0.037683
<4.0, ≥=4.0 6.578225 0.010323 2.178   (1.086-4.371) 0.028456
<3.5, ≥=3.5 13.267744 0.000270 3.705   (1.719-7.984) 0.000828
<3.0, ≥=3.0 16.097534 0.000060 4.831   (2.044-11.417) 0.000331
<2.5, ≥=2.5 13.896483 0.000193 4.640   (1.868-11.522) 0.000944
<2.0, ≥=2.0 11.625100 0.000651 4.983   (1.709-14.528) 0.003265
<1.5, ≥=1.5 7.895092 0.004957 5.931   (1.384-25.410) 0.016488
<1.0, ≥=1.0 2.478144 0.115438 4.111   (0.539-31.379) 0.172796
2. Stratification of preoperative serum CEA levels
To confirm the optimal classification of the serum CEA level, DFS and disease 
recurrence were compared between the groups with lower and higher CEA levels at 
each threshold. The log-rank test was used to compare DFS between the two groups. 
The preoperative serum CEA level with the highest chi-square value was regarded as 
the optimal critical point of classification. The most significant difference in DFS was 
detected at a threshold value of 3 ng/mL (χ2 = 16.097534, P = 0.000060). In addition, 
the most significant difference in recurrence was detected at a threshold value of 3 
ng/mL (hazard ratio [HR] 4.831, 95% confidence interval [CI] 2.044-11.417, P = 
0.000331). Thus, the critical cut-off value of the CEA level was defined as 3 ng/mL 
(Table 2).
Table 2. Chi-square values and hazard ratios according to preoperative serum CEA levels 
calculated by Cox proportional regression hazard model
CEA ≥3 ng/mL
(N=141)
CEA <3 ng/mL
(N=127)
P 
value
Age  60 (27-80) 59 (34-79) 0.876 
Sex Male 74 (52.5%) 64 (50.4%) 0.638 
Female 67 (47.5%) 63 (49.6%)
Location Ascending colon 37 (26.2%) 34 (26.8%) 0.862 
Transverse colon 11 (7.8%) 7 (5.5%)
Descending colon 6 (4.3%) 7 (5.5%)
Sigmoid colon 87 (61.7%) 79 (62.2%)
Ever smoking Never smoker 104 (73.8%) 106 (83.5%) 0.054
Ever smoker 37 (26.2%) 21 (16.5%)
Current 
smoking
Yes 13 (9.2%) 5 (3.9%) 0.084
No 128 (90.8%) 122 (96.1%)
Stage IIIA 6 (4.3%) 27 (21.3%) <0.001
IIIB 99 (70.2%) 75 (59.1%)
IIIC 36 (25.5%) 25 (19.7%)
3. Comparison of clinicopathological factors between patients with CEA levels <3 
ng/mL and ≥3 ng/mL
We observed a significant difference in the AJCC TNM stage between the patients with 
CEA levels above and below the cut-off level. Patients with high CEA levels 
(preoperative serum CEA level ≥ 3 ng/mL) tended to have a more advanced TNM 
stage (Table 3). There were no significant differences in age, sex, tumour location, 
smoking history, N stage, retrieved lymph node number, differentiation, 
lymphovascular invasion, perineural invasion, or adjuvant chemotherapeutic regimen 
between the two groups. Patients with high CEA levels experienced more events of 
recurrence compared to patients with low CEA levels (21.3% vs. 5.5%, P < 0.001)
Table 3. Patient characteristics
CEA ≥3 ng/mL
(N=141)
CEA <3 ng/mL
(N=127)
P 
value
T stage 0 0 (0.0%) 3 (2.4%) <0.001
1 2 (1.4%) 9 (7.1%)
2 3 (2.1%) 18 (14.2%)
3 108 (76.6%) 85 (66.9%)
4 28 (19.9%) 12 (9.4%)
N stage 1 94 (66.7%) 84 (66.1%) 0.928
2 47 (33.3%) 43 (33.9%)
No. of lymph 
nodes retrieved
<12 13 (9.2%) 8 (6.3%) 0.374
≥12 128 (90.8%) 119 (93.7%)
Differentiation Differentiated 131 (92.9%) 114 (89.8%) 0.359
Undifferentiated 10 (7.1%) 13 (10.2%)
LVI or PNI Absence 79 (56.0%) 81 (63.8%) 0.196
Presence 62 (44.0%) 46 (36.2%)
Adjuvant 
chemotherapy
FOLFOX 129 (91.5%) 120 (94.5%) 0.340
XELOX 12 (8.5%) 7 (5.5%)
K-RAS 
mutation
Wild type 77 (54.6%) 90 (70.9%) 0.006
Mutant type 64 (45.4%) 37 (29.1%)
4. Comparison of DFS and OS between patients with CEA levels <3 ng/mL and ≥3 
ng/mL
There were significant differences in DFS and OS between patients with lower and 
higher preoperative CEA levels (Fig. 3). The 5-year DFS rates of patients with low 
CEA and high CEA levels were 92.3% and 72.1%, respectively (P < 0.001) and hazard 
ratio for disease recurrence or death was 0.217 (95% CI 0.095 to 0.493; P < 0.001). The 
5-year OS rates of patients with low CEA and high CEA levels were 96.3% and 83.1%, 
respectively (P = 0.020) and hazard ratio for death was 0.253 (95% CI 0.072 to 0.887; P 
= 0.032). There was also a statistically significant difference in the pattern of recurrence 
between the two groups (Table 4). When analysis was performed in patients who 
experienced recurrence, patients with high CEA levels tended to have more local and 
systemic recurrence events than patients with low CEA levels (P = 0.032 for local 
recurrence and P = 0.001 for systemic recurrence).
Figure 3-A. Disease free survival according to preoperative serum CEA level
CEA ≥= 3 ng/mL 
(N=30)
CEA < 3ng/mL 
(N=7)
P value
Local recurrence 5 (16.7%) 0 (0.0%) 0.032
Anastomosis site 5 0
Systemic recurrence 28 (93.3%) 7 (100.0%) 0.001
Liver 10 3
Lung 10 2
Figure 3-B. Overall survival according to preoperative serum CEA level
Table 4. Patterns of recurrence according to preoperative serum CEA level
CEA ≥= 3 ng/mL 
(N=30)
CEA < 3ng/mL 
(N=7)
Ovary 3
Peritoneum 4 2
Distant lymph node 3 2
Bone 2 1
5. Prognostic variables for DFS and OS by univariate and multivariate analyses
On univariate analysis, advanced N stage (N2 vs. N1, 95% CI 1.205–4.306, HR 2.278, 
P = 0.011), poorly differentiated histology (poorly differentiated vs. well or moderately 
differentiated, 95% CI 1.247–6.437, HR 2.833, P = 0.013) and high preoperative serum 
CEA level (≥3 ng/mL vs. <3 ng/mL, 95% CI 2.028–10.474, HR 4.609, P < 0.001) 
(Table 5) were associated with reduced DFS. On multivariate analysis for the variables 
with P-value < 0.10 on univariate analysis (location, N stage, differentiation, 
lymphovascular invasion or perineural invasion, and preoperative serum CEA level), 
only high preoperative serum CEA level (95% CI 2.153–11.271, HR 4.926, P < 0.001) 
was associated with reduced DFS, but the associations of N stage (95% CI 0.837–3.684, 
HR 1.755, P = 0.137) and differentiation (95% CI 0.997-6.110, HR 2.468, P = 0.051) 
were lost.
Variable
Univariate hazard 
ratio
(95% CI)
P 
value
Multivariate hazard 
ratio
(95% CI)
P value
Age, ≥=65 years vs <65 
years
1.040 (0.538-2.012) 0.906
Sex, male vs female 1.083 (0.573-2.048) 0.806
Location, left vs right 1.719 (0.903-3.275) 0.099 1.255 (0.639-2.465) 0.509
T stage, 3-4 vs 0-2 2.479 (0.833-7.375) 0.103
N stage, 2 vs 1 2.278 (1.205-4.306) 0.011 1.755 (0.837-3.684) 0.137
No. of LN retrieved, <12 vs 
≥=12 
1.225 (0.434-3.457) 0.701
Undifferentiated vs 
differentiated
2.833 (1.247-6.437) 0.013 2.468 (0.997-6.110) 0.051
LVI or PNI 1.830 (0.968-3.461) 0.063 1.265 (0.638-2.509) 0.501
FOLFOX vs XELOX 1.169 (0.359-3.813) 0.795
CEA level, ≥= 3 ng/mL 4.609 (2.028-10.474)<0.001 4.926 (2.153-11.271) <0.001
Table 5. Univariate and multivariate model for disease free survival
6. Relationship between preoperative and postoperative serum CEA levels
For the 141 patients with high preoperative serum CEA levels (≥3 ng/mL), CEA levels 
remained above 3 ng/mL in 50 patients (35.5%) and decreased below 3 ng/mL in 91 
patients (64.5%). Of the 127 patients with low preoperative serum CEA levels (<3 
ng/mL), CEA levels increased to above 3 ng/mL in only 1 patient (0.8%, Table 6). In 
the patients with high preoperative serum CEA levels, there was no statistically 
significant difference in DFS by postoperative serum CEA levels (postoperative CEA 
level ≥3 ng/mL vs. <3 ng/mL, P = 0.223, Fig. 4).
　Postoperative CEA
Total<3 ng/mL ≥3 ng/mL
Preoperative CEA <3 ng/mL 126 (99.2%) 1 (0.8%) 127
≥3 ng/mL 91 (64.5%) 50 (35.5%) 141
Total 217 51 268
Table 6. Comparison between preoperative and postoperative serum CEA level
Figure 4. Disease free survival by preoperative and postoperative serum CEA level
IV. DISCUSSION
Serum CEA measurement is relatively cheap and easy to perform, and postoperative 
CEA level is commonly assessed in the follow-up of colorectal cancer patients [17]. 
CEA is overexpressed primarily by adenocarcinomas including those of the colon, 
rectum, breast, and lungs, and more than 90% of primary colorectal carcinomas produce 
CEA [18]. Patients with high CEA levels may have undetected occult metastases at the 
time of the operation. Lloyd et al. reported that, of stage I and II patients, 32.8% tested 
positive for disseminated tumour cells after surgery, and patients who were 
marker-positive for disseminated cells in post-resection lavage samples showed a 
significantly poorer prognosis. These reports suggested that residual tumour cells might 
be present even though curative resection was performed [19].
Previous reports usually defined 5 ng/mL as the cut-off value for the CEA level 
[20-21]. However, applying this cut-off value uniformly to different stages cannot 
adequately reflect oncologic outcomes. Wanebo et al. suggested that a preoperative 
CEA ≥ 5 ng/mL predicts a significant increase in recurrence rate for Dukes’ B patients, 
whereas for Dukes’ C patients, the increased recurrence rate was even more pronounced 
with a cut-off value of 10 ng/mL [22]. Golistin et al. and Lewi et al. showed that a 
preoperative CEA level ≥ 5 ng/mL is associated with poorer prognosis only in Dukes’ 
C disease, but not in Dukes’ B disease [23]. However, the study populations of these 
studies were heterogeneous in terms of neoadjuvant (chemo)radiotherapy, adjuvant 
chemotherapeutic regimens, and tumour location including the rectum. Thus, we 
investigated the optimal cut-off value for the CEA level in stage III colon cancer by 
using a homogeneous prospective cohort in terms of tumour location and adjuvant 
chemotherapeutic regimens including oxaliplatin.
The European MOSAIC trial reported on the efficacy of infused 5-FU, LV, and 
oxaliplatin (FOLFOX4) compared with 5-FU/LV in an adjuvant setting in 2,246 
patients with completely resected stage II and III colon cancer [3]. Based on the results 
of that trial, the addition of oxaliplatin to 5-FU/LV has been generally recommended as 
a treatment for stage III colon cancer in the NCCN guidelines. In this study, we contend 
that there is heterogeneity in biological aggressiveness and prognosis in stage III colon 
cancers that may be identifiable by using the preoperative CEA levels. We validated the 
usefulness of preoperative serum CEA level as a surrogate marker for relapse and 
survival for patients with stage III colon cancer. In accordance to findings in our study, 
individualization of the follow-up procedures for relapse and intensification of the 
follow-up procedures for high risk patients should be considered. Most previous studies 
of stage III colon cancer has not been used preoperative serum CEA level for the risk 
stratification of patients. In addition, they did not verify the optimal cut-off value of 
preoperative serum CEA in terms of DFS and OS, which indicate the clinical 
implications of our study.
Our study does have some limitations. First, the relatively smaller sample size assessed 
in a single institution should be re-evaluated in a large-scale multicentre validation. In 
addition, the results from the short follow-up period (median 37 months) need to be 
confirmed in future studies with longer follow-up periods. 
V. CONCLUSION
In conclusion, the preoperative CEA level is an independent prognostic factor for stage 
III colon cancer patients undergoing potentially curative resection followed by 
platinum-based double adjuvant chemotherapy. Inclusion of the preoperative serum 
CEA level should be considered for risk stratification, and patients with high 
preoperative CEA values should undergo intensive follow-up procedures for relapse. 
Additionally, further large-scale studies are necessary to determine the specific valid 
cut-off value for the preoperative CEA level to achieve a more accurate prognostic 
stratification.
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